Stefano Fontana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stefano Fontana has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Behrouz Mansouri Taleghani
From the Blood Transfusion Service Berne, Swiss Red Cross; and the Department of Hematology and Central Hematology Laboratory, Division of Transfusion Medicine, Inselspital, University of Berne, Berne, Switzerland
1 shared publicationChristoph Niederhauser
1 shared publication- Christoph Niederhauser
Interregional Blood Transfusion SRC, Bern, Switzerland
1 shared publication Hein Hustinx
1 shared publicationPeter Gowland
1 shared publication- Peter Gowland
Blood Transfusion Service Berne, Swiss Red Cross, Switzerland
1 shared publication
Latest Publications
- 1 January 2009
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 36 (3) , 228-229
Will Genotyping Replace Serology in Future Routine Blood Grouping? – Opinion 2
- 1 January 2009
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 36 (3) , 228-229
Will Genotyping Replace Serology in Future Routine Blood Grouping? – Opinion 2
- 22 October 2004
- Published by Wiley in Transfusion
- Vol. 44 (11) , 1555-1561
Molecular and serologic tracing of a transfusion‐transmitted hepatitis A virus
The transmission of hepatitis A virus (HAV) via blood transfusion has not been evidenced by molecular tracing so far. A 33-year-old asymptomatic female volunteer made a whole-blood donation. Thirteen days later an acute HAV infection was diagnosed. Retrospectively, a high viral load was measured by quantitative reverse transcription polymerase chain reaction (RT-PCR) in the quarantine fresh-frozen plasma (1.4 x 10(6) geq/mL), whereas immunoglobulin M (IgM) and G (IgG)/IgM anti-HAV were not detectable and the alanine aminotransferase levels not elevated. The red blood cells have just been transfused on Day 14. The 63-year-old male recipient already was HAV seropositive. He did not develop clinical symptoms of HAV and anti-HAV IgM was not detected. Seventy-five days later, a 25-fold increase in the anti-HAV IgG/IgM titer was observed. Demonstrable HAV ribonucleic acid (RNA) in the recipient by means of RT-PCR on Day 6, but not on Days 1 and 75, suggests that a transient reinfection did occur. Analyzed sequences of the HAV RNA in the donor and recipient were identical. For the first time, transfusion-transmitted HAV was evidenced by molecular and serologic tracing. The transmitted HAV can survive and replicate for a limited period despite the presence of anti-HAV IgG.
- 22 October 2004
- Published by Wiley in Transfusion
- Vol. 44 (11) , 1555-1561
Molecular and serologic tracing of a transfusion‐transmitted hepatitis A virus
The transmission of hepatitis A virus (HAV) via blood transfusion has not been evidenced by molecular tracing so far. A 33-year-old asymptomatic female volunteer made a whole-blood donation. Thirteen days later an acute HAV infection was diagnosed. Retrospectively, a high viral load was measured by quantitative reverse transcription polymerase chain reaction (RT-PCR) in the quarantine fresh-frozen plasma (1.4 x 10(6) geq/mL), whereas immunoglobulin M (IgM) and G (IgG)/IgM anti-HAV were not detectable and the alanine aminotransferase levels not elevated. The red blood cells have just been transfused on Day 14. The 63-year-old male recipient already was HAV seropositive. He did not develop clinical symptoms of HAV and anti-HAV IgM was not detected. Seventy-five days later, a 25-fold increase in the anti-HAV IgG/IgM titer was observed. Demonstrable HAV ribonucleic acid (RNA) in the recipient by means of RT-PCR on Day 6, but not on Days 1 and 75, suggests that a transient reinfection did occur. Analyzed sequences of the HAV RNA in the donor and recipient were identical. For the first time, transfusion-transmitted HAV was evidenced by molecular and serologic tracing. The transmitted HAV can survive and replicate for a limited period despite the presence of anti-HAV IgG.